PriceTargets.com logo

OTCMKTS:PETV - PetVivo Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 144.76 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.86 As of 11/26/2021 01:00 AM ET
▼ -0.05 (-1.72%)

This chart shows the closing price for PETV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PetVivo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PETV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PETV

Analyst Price Target is $7.00
▲ +144.76% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for PetVivo in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 144.76% upside from the last price of $2.86.

This chart shows the closing price for PETV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in PetVivo.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2021ThinkEquityInitiated CoverageBuy$7.00
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2021
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2021
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

PetVivo logo
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.
Read More

Today's Range

Now: $2.86
Low: $2.77
High: $2.90

50 Day Range

MA: $2.99
Low: $2.40
High: $5.01

52 Week Range

Now: $2.86
Low: $2.36
High: $17.00

Volume

72,233 shs

Average Volume

354,161 shs

Market Capitalization

$27.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of PetVivo?

The following sell-side analysts have issued stock ratings on PetVivo in the last year: ThinkEquity.
View the latest analyst ratings for PETV.

What is the current price target for PetVivo?

1 Wall Street analysts have set twelve-month price targets for PetVivo in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 144.8%. ThinkEquity has the highest price target set, predicting PETV will reach $7.00 in the next twelve months. ThinkEquity has the lowest price target set, forecasting a price of $7.00 for PetVivo in the next year.
View the latest price targets for PETV.

What is the current consensus analyst rating for PetVivo?

PetVivo currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PETV will outperform the market and that investors should add to their positions of PetVivo.
View the latest ratings for PETV.

What other companies compete with PetVivo?

Other companies that are similar to PetVivo include Neuronetics, T2 Biosystems, Sensus Healthcare, Acutus Medical, Pro-Dex, Titan Medical, Assure, LENSAR, RenovaCare, Venus Concept, Nephros, Lyra Therapeutics, Delcath Systems, Isoray and enVVeno Medical.

How do I contact PetVivo's investor relations team?

PetVivo's physical mailing address is 5251 EDINA INDUSTRIAL BLVD, EDINA MN, 55439. The company's listed phone number is (952) 405-6216. The official website for PetVivo is www.petvivo.com.